NCT03824561View on ClinicalTrials.gov

Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]

CompletedOBSERVATIONAL

Enrollment

1,110

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

February 12, 2025

Study Completion Date

February 12, 2025

Conditions

Ulcerative Colitis

Interventions

DRUG

Vedolizumab

Vedolizumab IV infusion

Trial Locations (1)

Unknown

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY